var data={"title":"Erythema elevatum diutinum","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Erythema elevatum diutinum</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/contributors\" class=\"contributor contributor_credentials\">Felipe Bochnia Cerci, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/contributors\" class=\"contributor contributor_credentials\">Joseph Jorizzo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/contributors\" class=\"contributor contributor_credentials\">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H676934464\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erythema elevatum diutinum (EED) is a chronic form of leukocytoclastic vasculitis consisting of violaceous, red-brown, or yellowish papules, plaques, or nodules that favor the extensor surfaces (<a href=\"image.htm?imageKey=DERM%2F67776%7EDERM%2F57008%7EDERM%2F101252%7EDERM%2F101253\" class=\"graphic graphic_picture graphicRef67776 graphicRef57008 graphicRef101252 graphicRef101253 \">picture 1A-D</a>) [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/1,2\" class=\"abstract_t\">1,2</a>]. EED may occur in association with infections, hematologic abnormalities, autoimmune diseases, or other conditions. Oral <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> is the primary mode of treatment.</p><p>The clinical features, diagnosis, and management of EED will be reviewed here. Other manifestations of cutaneous leukocytoclastic vasculitis are reviewed separately. (See <a href=\"topic.htm?path=evaluation-of-adults-with-cutaneous-lesions-of-vasculitis\" class=\"medical medical_review\">&quot;Evaluation of adults with cutaneous lesions of vasculitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H676934470\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EED is a rare disease that most frequently affects young and middle-aged adults between the ages of 30 and 60 years. There is no known sex or racial predilection [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H676934476\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of EED is not well understood. EED appears to be a form of immune complex-mediated vasculitis. The cutaneous findings may result from the deposition of immune complexes in small blood vessels in the skin, leading to complement activation, neutrophilic infiltration, and the release of destructive enzymes [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/4\" class=\"abstract_t\">4</a>]. In support of this theory, direct immunofluorescence studies reveal perivascular deposition of complement, IgG, IgM, IgA, and fibrin in EED [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/5\" class=\"abstract_t\">5</a>].</p><p>In addition, the findings of an in vitro study suggest that activation of cytokines such as interleukin-8 contributes to selective recruitment of leukocytes to affected skin [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/6\" class=\"abstract_t\">6</a>]. Antineutrophil cytoplasmic antibodies (ANCA) may also play a role in the pathogenesis of EED [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H676934482\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EED most commonly manifests as a bilateral eruption of violaceous, red-brown, or yellowish papules, plaques, or nodules (<a href=\"image.htm?imageKey=DERM%2F67776%7EDERM%2F57008%7EDERM%2F101252%7EDERM%2F101253\" class=\"graphic graphic_picture graphicRef67776 graphicRef57008 graphicRef101252 graphicRef101253 \">picture 1A-D</a>). Early EED tends to be soft and erythematous. Older lesions are often more firm secondary to fibrosis.</p><p>EED is most frequently found on acral skin and periarticular skin. The extensor surfaces of the elbows, knees, ankles, hands, and fingers are common locations [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/1,2\" class=\"abstract_t\">1,2</a>]. Less frequently involved sites include the face, retroauricular area, trunk, axillae, buttocks, and genitalia [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/8\" class=\"abstract_t\">8</a>].</p><p>Nodular lesions progressing to bulky masses appear to be more common in patients with EED associated with human immunodeficiency virus (HIV) infection than in other EED patients [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/9-12\" class=\"abstract_t\">9-12</a>]. Additional reported presentations of EED include annular plaques with raised borders [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/8\" class=\"abstract_t\">8</a>], verrucous plaques on the soles [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/13\" class=\"abstract_t\">13</a>], and vesicobullous presentations [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/14\" class=\"abstract_t\">14</a>]. (See <a href=\"#H676934488\" class=\"local\">'Associated disorders'</a> below.)</p><p>The cutaneous manifestations of EED may be asymptomatic or associated with a burning or stinging sensation or pruritus [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"abstract_t\">15</a>]. These symptoms are more likely to be present early in the course of disease. Extracutaneous symptoms may include arthralgia, fever, or other constitutional symptoms [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"abstract_t\">15</a>]. Ocular abnormalities, such as peripheral keratitis, nodular scleritis, panuveitis, and blindness also have been reported in patients with EED [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/16-18\" class=\"abstract_t\">16-18</a>]<em>.</em></p><p class=\"headingAnchor\" id=\"H676934488\"><span class=\"h1\">ASSOCIATED DISORDERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EED may occur in association with a number of systemic diseases. Examples of disorders that have been linked to EED in the literature include infections, hematologic disorders, and autoimmune diseases. However, data are insufficient for definitive conclusions on a causative relationship between these diseases and EED.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infection </strong>&ndash; Infections reported to occur in association with EED have included human immunodeficiency virus (HIV) infection [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/19-27\" class=\"abstract_t\">19-27</a>], beta-hemolytic streptococcal infections [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/28\" class=\"abstract_t\">28</a>], hepatitis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/29\" class=\"abstract_t\">29</a>], and tuberculosis. A literature review of published reports between 1977 and 2012 identified 19 reported cases of EED in association with HIV infection [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>]. The relationship between EED and HIV infection is postulated to involve immune complex deposition in blood vessels triggered by the HIV infection itself or other infections acting as antigenic stimuli [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/27\" class=\"abstract_t\">27</a>]. EED has occurred in HIV-positive patients with concomitant tuberculosis or hepatitis C [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/29,30\" class=\"abstract_t\">29,30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hematologic disorders </strong>&ndash; Hematologic disorders reported to occur in conjunction with EED include plasma cell dyscrasias (particularly IgA monoclonal gammopathies), myelodysplasia, myeloproliferative disorders, B-cell lymphoma, and hairy cell leukemia [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/1,31-35\" class=\"abstract_t\">1,31-35</a>]<em>. </em>EED may appear years after the diagnosis of the hematologic disease [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autoimmune disease </strong>&ndash; EED has occurred in patients with a variety of autoimmune and inflammatory diseases. Examples include inflammatory bowel disease [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/36,37\" class=\"abstract_t\">36,37</a>], rheumatoid arthritis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/38-40\" class=\"abstract_t\">38-40</a>], celiac disease [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/41-43\" class=\"abstract_t\">41-43</a>], relapsing polychondritis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/44,45\" class=\"abstract_t\">44,45</a>], lupus erythematosus [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/46-48\" class=\"abstract_t\">46-48</a>], granulomatous polyangiitis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/49\" class=\"abstract_t\">49</a>], and dermatomyositis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/50\" class=\"abstract_t\">50</a>].</p><p/><p>Other sporadic reports of disease associations include breast carcinoma [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/51\" class=\"abstract_t\">51</a>] and dermatitis herpetiformis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H676934494\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic features of EED vary over time (<a href=\"image.htm?imageKey=DERM%2F101415%7EDERM%2F101416\" class=\"graphic graphic_picture graphicRef101415 graphicRef101416 \">picture 2A-B</a>). Early EED exhibits leukocytoclastic vasculitis, demonstrating perivascular neutrophilic infiltrates in the upper and mid-dermis and fibrin deposition within or around the walls of small blood vessels [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>]. Lymphocytes, histiocytes, and (occasionally) a few eosinophils are also present. As the lesions mature, histiocytes and granulation tissue become more prevalent [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>].</p><p>Later-stage EED may exhibit dermal fibrosis with spindle cells and fibrinoid necrosis or fibrosis of capillary walls. Vertically oriented capillaries may be evident. In some cases, vasculitis is difficult to appreciate. Intracellular lipidosis manifesting as cholesterol clefts may be present [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/53\" class=\"abstract_t\">53</a>].</p><p class=\"headingAnchor\" id=\"H676934500\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of EED is made based upon correlation of the clinical and histologic findings. There are no serologic studies that confirm a diagnosis of EED.</p><p class=\"headingAnchor\" id=\"H676934506\"><span class=\"h2\">Clinical evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A full skin examination should be performed in patients with suspected EED. Clinical findings that strongly support a diagnosis of EED are violaceous, red-brown, or yellowish papules, plaques, or nodules that are symmetrically distributed on acral or periarticular sites (particularly the extensor surfaces of the elbows, knees, ankles, hands, and fingers). However, atypical distributions may also occur [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/54\" class=\"abstract_t\">54</a>]. Ulceration and vesiculation are rare findings.</p><p class=\"headingAnchor\" id=\"H676934512\"><span class=\"h2\">Skin biopsy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A skin biopsy is necessary to confirm the diagnosis. The biopsy specimen should contain the full thickness of the skin. We typically perform a punch biopsy that extends into the superficial subcutaneous fat.</p><p>Biopsy of a soft, early lesion is preferable to a biopsy of older, fibrotic lesions. Leukocytoclastic vasculitis is the key histologic finding of early EED. Granulation tissue, spindle cells, and fibrosis are common findings in later-stage EED. (See <a href=\"#H676934494\" class=\"local\">'Histopathology'</a> above.)</p><p>Direct immunofluorescence studies are usually not necessary for the evaluation of EED. If performed, perivascular deposits of fibrin, complement, and immunoglobulins may be seen [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H644334954\"><span class=\"h1\">EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Once the diagnosis of EED is made, the possibility of an associated disease should be considered. Appropriate initial tests to evaluate for underlying disease include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Complete blood count</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Comprehensive metabolic panel</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human immunodeficiency virus (HIV) test</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunofixation electrophoresis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antistreptolysin O or antideoxyribonuclease B titer</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatitis B and C serology</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antinuclear antibody (ANA)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antineutrophil cytoplasmic antibodies</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiphospholipid antibodies [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/55\" class=\"abstract_t\">55</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest radiograph</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Urinalysis</p><p/><p>Specific testing for other infections or autoimmune diseases should be based upon the presence of suggestive signs, symptoms, or patient history.</p><p>Because ocular abnormalities may occur in patients with EED, referral for ophthalmologic evaluation is appropriate for patients with ocular symptoms. (See <a href=\"#H676934482\" class=\"local\">'Clinical features'</a> above.)</p><p class=\"headingAnchor\" id=\"H676934518\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple disorders share clinical features with early or late-stage EED. Skin biopsy typically helps to distinguish between EED and other diseases.</p><p>The soft papules or plaques often representative of early EED may resemble extrafacial granuloma faciale, Sweet syndrome, rheumatoid neutrophilic dermatitis, or palisaded neutrophilic and granulomatous dermatitis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Granuloma faciale</strong> &ndash; Granuloma faciale is an uncommon disorder of unknown etiology characterized by one or more persistent, asymptomatic, smooth, red-brown or violaceous papules, plaques, or nodules, often with follicular prominence (<a href=\"image.htm?imageKey=DERM%2F50769\" class=\"graphic graphic_picture graphicRef50769 \">picture 3</a>). The face is the most common location. Histologic similarities between granuloma faciale and EED include inflammatory infiltrates containing neutrophils and eosinophils, as well as vasculitis and fibrosis on histopathologic examination. However, granuloma faciale may be more likely to exhibit a dense inflammatory infiltrate, plasma cells, and a predominance of eosinophils [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/56\" class=\"abstract_t\">56</a>]. In addition, the presence of granulomas may be more likely in EED. (See <a href=\"topic.htm?path=granuloma-faciale\" class=\"medical medical_review\">&quot;Granuloma faciale&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Sweet syndrome </strong>&ndash;<strong> </strong>Sweet syndrome is an acute neutrophilic dermatosis characterized by multiple tender, erythematous plaques or pustules on the face, neck, upper trunk, and extremities (<a href=\"image.htm?imageKey=DERM%2F85645%7EDERM%2F85646\" class=\"graphic graphic_picture graphicRef85645 graphicRef85646 \">picture 4A-B</a>). Associated fever, leukocytosis, arthralgias, myalgias, headaches, and general malaise are common. On histopathology, there is a diffuse neutrophilic infiltrate in the upper dermis. Unlike EED, leukocytoclastic vasculitis usually is absent. (See <a href=\"topic.htm?path=sweet-syndrome-acute-febrile-neutrophilic-dermatosis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rheumatoid neutrophilic dermatitis </strong>&ndash; Rheumatoid neutrophilic dermatitis (RND) classically presents as asymptomatic papulonodules or plaques distributed on the extensor surfaces of extremities (particularly the hands and forearms) as well as the neck and trunk (<a href=\"image.htm?imageKey=RHEUM%2F80854\" class=\"graphic graphic_picture graphicRef80854 \">picture 5</a>). RND usually occurs in association with rheumatoid arthritis, but can also develop in patients with seronegative arthritis. Histologic findings include a dense neutrophilic dermal infiltrate without vasculitis. (See <a href=\"topic.htm?path=neutrophilic-dermatoses#H32\" class=\"medical medical_review\">&quot;Neutrophilic dermatoses&quot;, section on 'Rheumatoid neutrophilic dermatitis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Palisaded neutrophilic and granulomatous dermatitis </strong>&ndash; Palisaded neutrophilic granulomatous dermatosis (PNGD) is a rare neutrophilic dermatosis with varied clinical presentations. The most common clinical presentation is erythematous papules symmetrically distributed on extensor surfaces of the upper extremities, especially the fingers and elbows. PNGD usually presents in patients with an underlying systemic condition such as rheumatoid arthritis and other autoimmune diseases, lymphoproliferative disorders, or infection. (See <a href=\"topic.htm?path=neutrophilic-dermatoses#H33\" class=\"medical medical_review\">&quot;Neutrophilic dermatoses&quot;, section on 'Palisaded neutrophilic granulomatous dermatitis'</a>.)</p><p/><p>Disorders in the differential diagnosis of late-stage EED primarily include disorders that may present with firm papules, plaques, or nodules on extensor surfaces, such as tuberous xanthomas, rheumatoid nodules, and multicentric reticulohistiocytosis.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tuberous xanthomas </strong>&ndash; Tuberous xanthomas&nbsp;present as pink-yellow papules or nodules on extensor surfaces, especially the elbows and knees (<a href=\"image.htm?imageKey=GAST%2F75143\" class=\"graphic graphic_picture graphicRef75143 \">picture 6</a>). Tuberous xanthomas occur in association with disorders of lipid or cholesterol metabolism. A biopsy reveals foamy cells and cholesterol clefts. (See <a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">&quot;Cutaneous xanthomas&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Rheumatoid nodules </strong>&ndash; Rheumatoid nodules&nbsp;are common in patients with rheumatoid arthritis. Affected patients develop firm, semi-mobile nodules that are several millimeters to a few centimeters in diameter (<a href=\"image.htm?imageKey=DERM%2F74194\" class=\"graphic graphic_picture graphicRef74194 \">picture 7</a>). Rheumatoid nodules&nbsp;are usually found in periarticular locations over extensor surfaces and in areas subject to pressure or trauma. The nodules are often asymptomatic, but may be tender or painful, particularly if there is associated trauma or ulceration. Histologic findings include a central zone of brightly eosinophilic fibrin surrounded by a palisaded layer of histiocytes and granulation tissue. Acute or early lesions may show leukocytoclastic vasculitis or an interstitial neutrophilic infiltrate. (See <a href=\"topic.htm?path=rheumatoid-nodules\" class=\"medical medical_review\">&quot;Rheumatoid nodules&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Multicentric reticulohistiocytosis </strong>&ndash; Multicentric reticulohistiocytosis is a disease characterized by cutaneous and mucous membrane reticulohistiocytomas and severe arthropathy. The cutaneous manifestations are skin-colored, pink, red-brown, or yellow papules or nodules that range from a few millimeters to 2 cm in diameter (<a href=\"image.htm?imageKey=DERM%2F77307\" class=\"graphic graphic_picture graphicRef77307 \">picture 8</a>). Favored sites include the head, hands, fingers, ears, and articular regions of the limbs. Small papules aligned along the periungual regions result in a characteristic &quot;coral bead&quot; appearance. Numerous multinucleated giant cells with eosinophilic, granular cytoplasm is the key histologic finding. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy#H28414907\" class=\"medical medical_review\">&quot;Cutaneous manifestations of internal malignancy&quot;, section on 'Multicentric reticulohistiocytosis'</a>.)</p><p/><p>Other granulomatous disorders (eg, granuloma annulare, sarcoidosis, leprosy, necrobiotic xanthogranuloma) may be considered in the differential diagnosis of EED. In addition, an isolated fibrotic papule, plaque or nodule of EED may resemble a dermatofibroma, dermatofibrosarcoma protuberans, or keloid. Occasionally, EED with a prominent vascular component, especially in an HIV-infected patient, might be mistaken for Kaposi sarcoma or bacillary angiomatosis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/11,30\" class=\"abstract_t\">11,30</a>].</p><p class=\"headingAnchor\" id=\"H676934590\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although EED is a benign and usually asymptomatic disorder, the chronic and disfiguring course drives most patients to seek treatment.</p><p class=\"headingAnchor\" id=\"H676934596\"><span class=\"h2\">First-line therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Due to the rarity of EED, there are limited data on the treatment of this disease. First-line treatment consists of <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> therapy based upon multiple reports of improvement in EED following use of this therapy. Treatment of an associated underlying disorder (if present) is also recommended [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>]. Improvement in EED has been reported after treatment of associated IgA paraproteinemia [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/31,57\" class=\"abstract_t\">31,57</a>], B-cell lymphoma [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/35\" class=\"abstract_t\">35</a>], ulcerative colitis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/37\" class=\"abstract_t\">37</a>], and pulmonary lymphoepithelioma-like carcinoma [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/58\" class=\"abstract_t\">58</a>].</p><p class=\"headingAnchor\" id=\"H676934602\"><span class=\"h3\">Dapsone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> is the medical treatment of choice for EED.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Efficacy </strong>&ndash; Use of <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> for EED is primarily supported by multiple case reports and small case series [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/6,10,12,16,21,23,25,28,30,33,35,38,48,59-63\" class=\"abstract_t\">6,10,12,16,21,23,25,28,30,33,35,38,48,59-63</a>]. A review of the literature published from 1977 to 2012 identified 66 reported cases of EED treated with dapsone, including 59 treated with dapsone monotherapy. Of the 59, dapsone therapy was associated with a reduction in lesion size or complete resolution of EED in 47 patients (80 percent) [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>]. No randomized trials have evaluated dapsone for EED.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> is often ineffective for fibrotic nodular EED [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/3,8,11\" class=\"abstract_t\">3,8,11</a>]. Therefore, dapsone may be most beneficial for early disease. (See <a href=\"#H676934482\" class=\"local\">'Clinical features'</a> above and <a href=\"#H676934494\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\">In addition to cutaneous disease, <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> may improve extracutaneous symptoms. Arthralgias and ocular symptoms have improved during dapsone treatment [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12,18\" class=\"abstract_t\">12,18</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Administration </strong>&ndash;<strong> </strong><a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> therapy for EED has been given in doses ranging from 50 to 300 mg per day [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"abstract_t\">12</a>]. A lower dose is typically administered (25 to 50 mg) at the start of treatment. The dose is then titrated upward dependent on patient tolerance and response to therapy. The usual adult dose for EED is&nbsp;100 mg per day.</p><p/><p class=\"bulletIndent1\">Benefit of <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> for EED may be dose dependent [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/64\" class=\"abstract_t\">64</a>]. Reductions in the size of EED lesions may be evident within the first few months of treatment [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/6,65\" class=\"abstract_t\">6,65</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Adverse effects </strong>&ndash; <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">Dapsone</a> therapy is associated with risk for a variety of adverse effects, including hemolysis, agranulocytosis, methemoglobinemia, dapsone hypersensitivity syndrome, and peripheral neuropathy (<a href=\"image.htm?imageKey=DERM%2F86540\" class=\"graphic graphic_table graphicRef86540 \">table 1</a>). Although hemolysis occurs to some degree in all patients, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at increased risk for severe hemolytic anemia. Therefore, screening for G6PD deficiency should be performed prior to initiating dapsone therapy. Periodic laboratory monitoring for hematologic or liver abnormalities is also indicated during dapsone therapy. (See <a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency#H5\" class=\"medical medical_review\">&quot;Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency&quot;, section on 'Acute hemolytic anemia'</a> and <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H676934608\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other local, surgical, and systemic therapies for EED have been reported to improve EED in small numbers of patients. Although these treatments may benefit some patients, there are fewer data on the efficacy of these therapies than for <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>, precluding a recommendation for use as first-line therapy.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Local treatment </strong>&ndash; Potent topical corticosteroids and intralesional corticosteroid injections have been administered for EED with variable results [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"abstract_t\">15</a>]. Potential benefit of topical <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> is suggested by a case report in which application of dapsone 5% gel to EED for one week prior to the start of oral dapsone therapy was associated with improvement in erythema and flattening of lesions [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/66\" class=\"abstract_t\">66</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Systemic treatment </strong>&ndash; Systemic therapies reported as effective in a few patients have included a variety of agents with antimicrobial, antiinflammatory, or immunosuppressive properties. Improvement in EED has been reported after treatment with sulfapyridine or sulfamethoxypyridazine [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12,64\" class=\"abstract_t\">12,64</a>] as well as <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> plus niacinamide [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/67\" class=\"abstract_t\">67</a>]. In addition, individual patients have seemed to respond to regimens of <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">colchicine</a> [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/68\" class=\"abstract_t\">68</a>], <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/69\" class=\"abstract_t\">69</a>], <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/64\" class=\"abstract_t\">64</a>], phenformin [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/70\" class=\"abstract_t\">70</a>], and <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a> combined with <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/71\" class=\"abstract_t\">71</a>]. Antibiotics such as <a href=\"topic.htm?path=clarithromycin-drug-information\" class=\"drug drug_general\">clarithromycin</a>, <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">erythromycin</a>, and penicillin have also been administered for EED in combination with surgical excision or dapsone, with varying outcomes [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/11\" class=\"abstract_t\">11</a>].</p><p/><p class=\"bulletIndent1\">Oral glucocorticoids may improve EED when used alone or in conjunction with <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> or other therapy [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12,44,50\" class=\"abstract_t\">12,44,50</a>]. However, oral glucocorticoids are rarely indicated due to the risk for serious adverse effects with long-term glucocorticoid therapy. (See <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgery </strong>&ndash; Fibrotic nodules often respond poorly to <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>. Local surgical excision can be beneficial for localized fibrotic nodules of EED [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/72,73\" class=\"abstract_t\">72,73</a>].</p><p/><p class=\"headingAnchor\" id=\"H676934638\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>EED usually has a prolonged course, characterized by fluctuating periods of exacerbation and stability. The disease may resolve spontaneously after 5 to 10 years; however, persistence up to 40 years has occurred [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/3,64\" class=\"abstract_t\">3,64</a>]. EED does not progress to systemic vasculitis [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"abstract_t\">15</a>]. Recurrence is common after cessation of <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> therapy [<a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H676934644\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythema elevatum diutinum (EED) is a rare form of leukocytoclastic vasculitis consisting of violaceous, red-brown, or yellowish papules, plaques, or nodules that favor the extensor surfaces (<a href=\"image.htm?imageKey=DERM%2F67776%7EDERM%2F57008%7EDERM%2F101252%7EDERM%2F101253\" class=\"graphic graphic_picture graphicRef67776 graphicRef57008 graphicRef101252 graphicRef101253 \">picture 1A-D</a>). EED is most common in adults between the ages of 30 and 60 years. (See <a href=\"#H676934482\" class=\"local\">'Clinical features'</a> above and <a href=\"#H676934470\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The pathogenesis of EED is not well understood. EED may represent an immune complex-mediated vasculitis. The disorder may occur in association with infections, hematologic disorders, or autoimmune diseases. (See <a href=\"#H676934476\" class=\"local\">'Pathogenesis'</a> above and <a href=\"#H676934488\" class=\"local\">'Associated disorders'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of EED is made based upon correlation of the clinical and histologic findings. (See <a href=\"#H676934500\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatments for EED have included local medications, systemic medications, and surgery. We suggest oral <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a> as initial treatment based upon multiple case reports and small case series that suggest efficacy and the well-tolerated nature of this treatment (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). In addition, the associated underlying disease (when present) should be treated. (See <a href=\"#H676934596\" class=\"local\">'First-line therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Erythema elevatum diutinum exhibits a prolonged course, characterized by fluctuating periods of exacerbation and stability. (See <a href=\"#H676934638\" class=\"local\">'Prognosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/1\" class=\"nounderline abstract_t\">Yiannias JA, el-Azhary RA, Gibson LE. Erythema elevatum diutinum: a clinical and histopathologic study of 13 patients. J Am Acad Dermatol 1992; 26:38.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/2\" class=\"nounderline abstract_t\">Mraz JP, Newcomer VD. Erythema elevatum diutinum. Presentation of a case and evaluation of laboratory and immunological status. Arch Dermatol 1967; 96:235.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/3\" class=\"nounderline abstract_t\">High WA, Hoang MP, Stevens K, Cockerell CJ. Late-stage nodular erythema elevatum diutinum. J Am Acad Dermatol 2003; 49:764.</a></li><li class=\"breakAll\">Shinkai K, Fox LP. Cutaneous vasculitis. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer J.  (Eds), Elsevier Limited, 2012. Vol 1, p.385.</li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/5\" class=\"nounderline abstract_t\">Shimizu S, Nakamura Y, Togawa Y, et al. Erythema elevatum diutinum with primary Sj&ouml;gren syndrome associated with IgA antineutrophil cytoplasmic antibody. Br J Dermatol 2008; 159:733.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/6\" class=\"nounderline abstract_t\">Grabbe J, Haas N, M&ouml;ller A, Henz BM. Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol 2000; 143:415.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/7\" class=\"nounderline abstract_t\">Ayoub N, Charuel JL, Diemert MC, et al. Antineutrophil cytoplasmic antibodies of IgA class in neutrophilic dermatoses with emphasis on erythema elevatum diutinum. Arch Dermatol 2004; 140:931.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/8\" class=\"nounderline abstract_t\">Di Giacomo TB, Marinho RT, Nico MM. Erythema elevatum diutinum presenting with a giant annular pattern. Int J Dermatol 2009; 48:290.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/9\" class=\"nounderline abstract_t\">da Cunha Bang F, Weismann K, Ralfkiaer E, et al. Erythema elevatum diutinum and pre-AIDS. Acta Derm Venereol 1986; 66:272.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/10\" class=\"nounderline abstract_t\">Dronda F, Gonz&aacute;lez-L&oacute;pez A, Lecona M, Barros C. Erythema elevatum diutinum in human immunodeficiency virus-infected patients--report of a case and review of the literature. Clin Exp Dermatol 1996; 21:222.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/11\" class=\"nounderline abstract_t\">Muratori S, Carrera C, Gorani A, Alessi E. Erythema elevatum diutinum and HIV infection: a report of five cases. Br J Dermatol 1999; 141:335.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/12\" class=\"nounderline abstract_t\">Momen SE, Jorizzo J, Al-Niaimi F. Erythema elevatum diutinum: a review of presentation and treatment. J Eur Acad Dermatol Venereol 2014; 28:1594.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/13\" class=\"nounderline abstract_t\">Barzegar M, Davatchi CC, Akhyani M, et al. An atypical presentation of erythema elevatum diutinum involving palms and soles. Int J Dermatol 2009; 48:73.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/14\" class=\"nounderline abstract_t\">Tomasini C, Seia Z, Dapavo P, et al. Infantile erythema elevatum diutinum: report of a vesiculo-bullous case. Eur J Dermatol 2006; 16:683.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/15\" class=\"nounderline abstract_t\">Gibson LE, el-Azhary RA. Erythema elevatum diutinum. Clin Dermatol 2000; 18:295.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/16\" class=\"nounderline abstract_t\">Aldave AJ, Shih JL, Jovkar S, McLeod SD. Peripheral keratitis associated with erythema elevatum diutinum. Am J Ophthalmol 2003; 135:389.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/17\" class=\"nounderline abstract_t\">Mitamura Y, Fujiwara O, Miyanishi K, et al. Nodular scleritis and panuveitis with erythema elevatum diutinum. Am J Ophthalmol 2004; 137:368.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/18\" class=\"nounderline abstract_t\">Lekhanont K, Patarakittam T, Mantachote K, et al. Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. Ophthalmology 2011; 118:927.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/19\" class=\"nounderline abstract_t\">Smitha P, Sathish P, Mohan K, et al. A case of extensive erosive and bullous erythema elevatum diutinum in a patient diagnosed with human immunodeficiency virus (HIV). Int J Dermatol 2011; 50:989.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/20\" class=\"nounderline abstract_t\">Prabhu S, Shenoi SD, Kishanpuria PS, Pai SB. Erythema elevatum diutinum associated with scleritis. Indian Dermatol Online J 2011; 2:28.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/21\" class=\"nounderline abstract_t\">Rover PA, Bittencourt C, Discacciati MP, et al. Erythema elevatum diutinum as a first clinical manifestation for diagnosing HIV infection: case history. Sao Paulo Med J 2005; 123:201.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/22\" class=\"nounderline abstract_t\">Mart&iacute;n JI, Dronda F, Chaves F. Erythema elevatum diutinum, a clinical entity to be considered in patients infected with HIV-1. Clin Exp Dermatol 2001; 26:725.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/23\" class=\"nounderline abstract_t\">Fakheri A, Gupta SM, White SM, et al. Erythema elevatum diutinum in a patient with human immunodeficiency virus. Cutis 2001; 68:41.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/24\" class=\"nounderline abstract_t\">Sanz-Trelles A, Ayala-Carbonero A, Ojeda-Martos A. Erythema elevatum diutinum in an HIV+ hemophilic patient. Am J Dermatopathol 1999; 21:587.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/25\" class=\"nounderline abstract_t\">Su&aacute;rez J, Migu&eacute;lez M, Villalba R. Nodular erythema elevatum diutinum in an HIV-1 infected woman: response to dapsone and antiretroviral therapy. Br J Dermatol 1998; 138:717.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/26\" class=\"nounderline abstract_t\">Soni BP, Williford PM, White WL. Erythematous nodules in a patient infected with the human immunodeficiency virus. Erythema elevatum diutinum (EED). Arch Dermatol 1998; 134:232.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/27\" class=\"nounderline abstract_t\">LeBoit PE, Cockerell CJ. Nodular lesions of erythema elevatum diutinum in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1993; 28:919.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/28\" class=\"nounderline abstract_t\">Cream JJ, Levene GM, Calnan CD. Erythema elevatum diutinum: an unusual reaction to streptococcal antigen and response to dapsone. Br J Dermatol 1971; 84:393.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/29\" class=\"nounderline abstract_t\">Kim H. Erythema elevatum diutinum in an HIV-positive patient. J Drugs Dermatol 2003; 2:411.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/30\" class=\"nounderline abstract_t\">Requena L, S&aacute;nchez Yus E, Mart&iacute;n L, et al. Erythema elevatum diutinum in a patient with acquired immunodeficiency syndrome. Another clinical simulator of Kaposi's sarcoma. Arch Dermatol 1991; 127:1819.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/31\" class=\"nounderline abstract_t\">Chow RK, Benny WB, Coupe RL, et al. Erythema elevatum diutinum associated with IgA paraproteinemia successfully controlled with intermittent plasma exchange. Arch Dermatol 1996; 132:1360.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/32\" class=\"nounderline abstract_t\">Wayte JA, Rogers S, Powell FC. Pyoderma gangrenosum, erythema elevatum diutinum and IgA monoclonal gammopathy. Australas J Dermatol 1995; 36:21.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/33\" class=\"nounderline abstract_t\">Katz SI, Gallin JI, Hertz KC, et al. Erythema elevatum diutinum: skin and systemic manifestations, immunologic studies, and successful treatment with dapsone. Medicine (Baltimore) 1977; 56:443.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/34\" class=\"nounderline abstract_t\">Delaporte E, Alfandari S, Fenaux P, et al. Erythema elevatum diutinum and chronic lymphocytic leukemia. Clin Exp Dermatol 1994; 19:188.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/35\" class=\"nounderline abstract_t\">Futei Y, Konohana I. A case of erythema elevatum diutinum associated with B-cell lymphoma: a rare distribution involving palms, soles and nails. Br J Dermatol 2000; 142:116.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/36\" class=\"nounderline abstract_t\">Walker KD, Badame AJ. Erythema elevatum diutinum in a patient with Crohn's disease. J Am Acad Dermatol 1990; 22:948.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/37\" class=\"nounderline abstract_t\">Buahene K, Hudson M, Mowat A, et al. Erythema elevatum diutinum--an unusual association with ulcerative colitis. Clin Exp Dermatol 1991; 16:204.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/38\" class=\"nounderline abstract_t\">Nakajima H, Ikeda M, Yamamoto Y, Kodama H. Erythema elevatum diutinum complicated by rheumatoid arthritis. J Dermatol 1999; 26:452.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/39\" class=\"nounderline abstract_t\">Collier PM, Neill SM, Branfoot AC, Staughton RC. Erythema elevatum diutinum--a solitary lesion in a patient with rheumatoid arthritis. Clin Exp Dermatol 1990; 15:394.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/40\" class=\"nounderline abstract_t\">Grupper C, Edelson Y. [Erythema elevatum diutinum associated with rheumatoid polyarthritis]. Bull Soc Fr Dermatol Syphiligr 1969; 76:759.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/41\" class=\"nounderline abstract_t\">Rodriguez-Serna M, Fortea JM, Perez A, et al. Erythema elevatum diutinum associated with celiac disease: response to a gluten-free diet. Pediatr Dermatol 1993; 10:125.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/42\" class=\"nounderline abstract_t\">Tasanen K, Raudasoja R, Kallioinen M, Ranki A. Erythema elevatum diutinum in association with coeliac disease. Br J Dermatol 1997; 136:624.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/43\" class=\"nounderline abstract_t\">Kwon JL, Sigal AC, Bossenbroek NM. Erythema elevatum diutinum in association with celiac disease. Int J Dermatol 2009; 48:787.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/44\" class=\"nounderline abstract_t\">Delgado J, G&oacute;mez-Cerezo J, Sig&uuml;enza M, et al. Relapsing polychondritis and erythema elevatum diutinum: an unusual association refractory to dapsone. J Rheumatol 2001; 28:634.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/45\" class=\"nounderline abstract_t\">Bernard P, Bedane C, Delrous JL, et al. Erythema elevatum diutinum in a patient with relapsing polychondritis. J Am Acad Dermatol 1992; 26:312.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/46\" class=\"nounderline abstract_t\">Hancox JG, Wallace CA, Sangueza OP, Graham GF. Erythema elevatum diutinum associated with lupus panniculitis in a patient with discoid lesions of chronic cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 50:652.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/47\" class=\"nounderline abstract_t\">Woody CM, Lane JE, Davis LS. Erythema elevatum diutinum in the setting of connective tissue disease and chronic bacterial infection. J Clin Rheumatol 2005; 11:98.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/48\" class=\"nounderline abstract_t\">Chan Y, Mok CC, Tang WY. Erythema elevatum diutinum in systemic lupus erythematosus. Rheumatol Int 2011; 31:259.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/49\" class=\"nounderline abstract_t\">Kavanagh GM, Colaco CB, Bradfield JW, Archer CB. Erythema elevatum diutinum associated with Wegener's granulomatosis and IgA paraproteinemia. J Am Acad Dermatol 1993; 28:846.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/50\" class=\"nounderline abstract_t\">Marie I, Courville P, Levesque H. Erythema elevatum diutinum associated with dermatomyositis. J Am Acad Dermatol 2011; 64:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/51\" class=\"nounderline abstract_t\">Yilmaz F, Arta&ccedil; M, Cift&ccedil;ioglu MA, Yilmaz E. A case of erythema elevatum diutinum associated with breast carcinoma. Int J Dermatol 2005; 44:948.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/52\" class=\"nounderline abstract_t\">Aftab MN, Dee A, Helm TN. Erythema elevatum diutinum arising in the setting of dermatitis herpetiformis. Cutis 2006; 78:129.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/53\" class=\"nounderline abstract_t\">Kanitakis J, Cozzani E, Lyonnet S, Thivolet J. Ultrastructural study of chronic lesions of erythema elevatum diutinum: &quot;extracellular cholesterosis&quot; is a misnomer. J Am Acad Dermatol 1993; 29:363.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/54\" class=\"nounderline abstract_t\">Ben-Zvi GT, Bardsley V, Burrows NP. An atypical distribution of erythema elevatum diutinum. Clin Exp Dermatol 2014; 39:269.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/55\" class=\"nounderline abstract_t\">Lisi S, Mussi A, Muscardin L, Carducci M. A case of erythema elevatum diutinum associated with antiphospholipid antibodies. J Am Acad Dermatol 2003; 49:963.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/56\" class=\"nounderline abstract_t\">Ziemer M, Koehler MJ, Weyers W. Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? J Cutan Pathol 2011; 38:876.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/57\" class=\"nounderline abstract_t\">Manni E, Cervadoro E, Papineschi F. Case of erythema elevatum diutinum associated with IgA paraproteinemia successfully controlled with thalidomide and plasma exchange. Ther Apher Dial 2015; 19:195.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/58\" class=\"nounderline abstract_t\">Liu TC, Chen IS, Lin TK, et al. Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma. Lung Cancer 2009; 63:151.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/59\" class=\"nounderline abstract_t\">Caputo R, Alessi E. Unique aspects of a lesion of erythema elevatum diutinum. Am J Dermatopathol 1984; 6:465.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/60\" class=\"nounderline abstract_t\">Fort SL, Rodman OG. Erythema elevatum diutinum. Response to dapsone. Arch Dermatol 1977; 113:819.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/61\" class=\"nounderline abstract_t\">Elsner J, Kiehl P, Kapp A, Weiss J. [Erythema elevatum and diutinum in Crohn disease]. Hautarzt 1996; 47:701.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/62\" class=\"nounderline abstract_t\">Planagum&agrave; M, Puig L, Alomar A, et al. Pyoderma gangrenosum in association with erythema elevatum diutinum: report of two cases. Cutis 1992; 49:201.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/63\" class=\"nounderline abstract_t\">Vaiyavatjamai P, Wattanakrai P. Erythema elevatum diutinum associated with peripheral ulcerative keratitis. J Eur Acad Dermatol Venereol 2011; 25:741.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/64\" class=\"nounderline abstract_t\">Wilkinson SM, English JS, Smith NP, et al. Erythema elevatum diutinum: a clinicopathological study. Clin Exp Dermatol 1992; 17:87.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/65\" class=\"nounderline abstract_t\">Galeone M, Arunachalam M, Bassi A, et al. Erythema elevatum diutinum. QJM 2014; 107:227.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/66\" class=\"nounderline abstract_t\">Frieling GW, Williams NL, Lim SJ, Rosenthal SI. Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. J Drugs Dermatol 2013; 12:481.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/67\" class=\"nounderline abstract_t\">Kohler IK, Lorincz AL. Erythema elevatum diutinum treated with niacinamide and tetracycline. Arch Dermatol 1980; 116:693.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/68\" class=\"nounderline abstract_t\">Henriksson R, Hofer PA, H&ouml;rnqvist R. Erythema elevatum diutinum--a case successfully treated with colchicine. Clin Exp Dermatol 1989; 14:451.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/69\" class=\"nounderline abstract_t\">Chowdhury MM, Inaloz HS, Motley RJ, Knight AG. Erythema elevatum diutinum and IgA paraproteinaemia: 'a preclinical iceberg'. Int J Dermatol 2002; 41:368.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/70\" class=\"nounderline abstract_t\">Schumacher HR, Carroll E, Taylor F, et al. Erythema elevatum diutinum: cutaneous vasculitis, impaired clot lysis, and response to phenformin. J Rheumatol 1977; 4:103.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/71\" class=\"nounderline abstract_t\">Takahashi H, Fukami Y, Honma M, et al. Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. J Dermatol 2012; 39:486.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/72\" class=\"nounderline abstract_t\">Zacaron LH, Gon&ccedil;alves JC, Curty VM, et al. Clinical and surgical therapeutic approach in erithema elevatum diutinum--case report. An Bras Dermatol 2013; 88:15.</a></li><li><a href=\"https://www.uptodate.com/contents/erythema-elevatum-diutinum/abstract/73\" class=\"nounderline abstract_t\">Rinard JR, Mahabir RC, Greene JF, Grothaus P. Successful surgical treatment of advanced erythema elevatum diutinum. Can J Plast Surg 2010; 18:28.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13765 Version 3.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H676934644\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H676934464\" id=\"outline-link-H676934464\">INTRODUCTION</a></li><li><a href=\"#H676934470\" id=\"outline-link-H676934470\">EPIDEMIOLOGY</a></li><li><a href=\"#H676934476\" id=\"outline-link-H676934476\">PATHOGENESIS</a></li><li><a href=\"#H676934482\" id=\"outline-link-H676934482\">CLINICAL FEATURES</a></li><li><a href=\"#H676934488\" id=\"outline-link-H676934488\">ASSOCIATED DISORDERS</a></li><li><a href=\"#H676934494\" id=\"outline-link-H676934494\">HISTOPATHOLOGY</a></li><li><a href=\"#H676934500\" id=\"outline-link-H676934500\">DIAGNOSIS</a><ul><li><a href=\"#H676934506\" id=\"outline-link-H676934506\">Clinical evaluation</a></li><li><a href=\"#H676934512\" id=\"outline-link-H676934512\">Skin biopsy</a></li></ul></li><li><a href=\"#H644334954\" id=\"outline-link-H644334954\">EVALUATION</a></li><li><a href=\"#H676934518\" id=\"outline-link-H676934518\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H676934590\" id=\"outline-link-H676934590\">TREATMENT</a><ul><li><a href=\"#H676934596\" id=\"outline-link-H676934596\">First-line therapy</a><ul><li><a href=\"#H676934602\" id=\"outline-link-H676934602\">- Dapsone</a></li></ul></li><li><a href=\"#H676934608\" id=\"outline-link-H676934608\">Other therapies</a></li></ul></li><li><a href=\"#H676934638\" id=\"outline-link-H676934638\">PROGNOSIS</a></li><li><a href=\"#H676934644\" id=\"outline-link-H676934644\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/13765|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/67776\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum - upper extremities</a></li><li><a href=\"image.htm?imageKey=DERM/57008\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum - lower extremities</a></li><li><a href=\"image.htm?imageKey=DERM/101252\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum nodular</a></li><li><a href=\"image.htm?imageKey=DERM/101253\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum on arm</a></li><li><a href=\"image.htm?imageKey=DERM/101415\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/101416\" class=\"graphic graphic_picture\">- Erythema elevatum diutinum histopathology 2</a></li><li><a href=\"image.htm?imageKey=DERM/50769\" class=\"graphic graphic_picture\">- Granuloma faciale</a></li><li><a href=\"image.htm?imageKey=DERM/85645\" class=\"graphic graphic_picture\">- Sweet syndrome plaques on arm</a></li><li><a href=\"image.htm?imageKey=DERM/85646\" class=\"graphic graphic_picture\">- Sweet syndrome plaques on legs</a></li><li><a href=\"image.htm?imageKey=RHEUM/80854\" class=\"graphic graphic_picture\">- Rheumatoid neutroph dermatitis</a></li><li><a href=\"image.htm?imageKey=GAST/75143\" class=\"graphic graphic_picture\">- Tuberous xanthomas in PBC</a></li><li><a href=\"image.htm?imageKey=DERM/74194\" class=\"graphic graphic_picture\">- Rheumatoid nodules</a></li><li><a href=\"image.htm?imageKey=DERM/77307\" class=\"graphic graphic_picture\">- Multicentric reticulohistiocytosis</a></li></ul></li><li><div id=\"DERM/13765|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/86540\" class=\"graphic graphic_table\">- Adverse effects of dapsone</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-internal-malignancy\" class=\"medical medical_review\">Cutaneous manifestations of internal malignancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-xanthomas\" class=\"medical medical_review\">Cutaneous xanthomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-glucose-6-phosphate-dehydrogenase-deficiency\" class=\"medical medical_review\">Diagnosis and management of glucose-6-phosphate dehydrogenase deficiency</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-adults-with-cutaneous-lesions-of-vasculitis\" class=\"medical medical_review\">Evaluation of adults with cutaneous lesions of vasculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=granuloma-faciale\" class=\"medical medical_review\">Granuloma faciale</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neutrophilic-dermatoses\" class=\"medical medical_review\">Neutrophilic dermatoses</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rheumatoid-nodules\" class=\"medical medical_review\">Rheumatoid nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sweet-syndrome-acute-febrile-neutrophilic-dermatosis-pathogenesis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis</a></li></ul></div></div>","javascript":null}